Repligen Corporation (RGEN)

Market Cap	9.29B
Revenue (ttm)	638.76M
Net Income (ttm)	41.58M
Shares Out	55.77M
EPS (ttm)	0.74
PE Ratio	225.11
Forward PE	112.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,837
Open	165.66
Previous Close	165.66
Day's Range	165.05 - 168.46
52-Week Range	110.45 - 211.13
Beta	1.01
Analysts	Strong Buy
Price Target	199.00 (+19.46%)
Earnings Date	May 1, 2024

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,783
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN

Financial Performance

In 2023, Repligen's revenue was $638.76 million, a decrease of -20.31% compared to the previous year's $801.54 million. Earnings were $41.58 million, a decrease of -77.64%.

Analyst Forecast

According to 9 analysts, the average rating for RGEN stock is "Strong Buy." The 12-month stock price forecast is $199.0, which is an increase of 19.46% from the latest price.

Price Target

$199.0

(19.46% upside)

Analyst Consensus: Strong Buy